CD7 CAR iNKT-cells prepared by researchers using donor-iNKT-cells are more effective in 70% of CD7+CD1d+T-ALL patients because they provide dual target specificity and reduce the possibility of relapse (81). The gene discussed is CD7; the disease is acute lymphoblastic leukemia.